UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study

Molecular psychiatry, 2016-01, Vol.21 (1), p.71-79

2016

Volltextzugriff (PDF)

A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients

Molecular psychiatry, 2016-10, Vol.21 (10), p.1372-1380

2016

Volltextzugriff (PDF)

Interleukin-6 receptor antagonists in immunopsychiatry: Can they lead to increased interleukin-6 in the central nervous system (CNS) and worsening psychiatric symptoms?

Brain, behavior, and immunity, 2022-07, Vol.103, p.202-204

2022

Volltextzugriff (PDF)

Dissociable cortico-striatal connectivity abnormalities in major depression in response to monetary gains and penalties

Psychological medicine, 2015-01, Vol.45 (1), p.121-131

2015

Volltextzugriff (PDF)

Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression

Molecular psychiatry, 2012-12, Vol.17 (12), p.1161-1163

2012

Volltextzugriff (PDF)

Reduced frontal-subcortical white matter connectivity in association with suicidal ideation in major depressive disorder

Translational psychiatry, 2016-06, Vol.6 (6), p.e835-e835

2016

Volltextzugriff (PDF)

Complementary Medicine, Exercise, Meditation, Diet, and Lifestyle Modification for Anxiety Disorders: A Review of Current Evidence

Evidence-based complementary and alternative medicine, 2012-01, Vol.2012 (2012), p.1-20

2012

Volltextzugriff (PDF)

St John's wort (Hypericum perforatum) versus sertraline and placebo in major depressive disorder: continuation data from a 26-week RCT

Pharmacopsychiatry, 2012-11, Vol.45 (7), p.275-278

2012

Volltextzugriff (PDF)

Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re-Analysis of Data from a Randomized Clinical Trial

Pharmacopsychiatry, 2015-07, Vol.48 (4-5), p.141-144

2015

Volltextzugriff (PDF)

Corrigendum to “Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants” [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1]

Journal of affective disorders, 2018-02, Vol.227, p.198-198

2018

Volltextzugriff (PDF)

A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients

Molecular psychiatry, 2016-10, Vol.21 (10), p.1483-1484

2016

Volltextzugriff (PDF)

P.1.k.023 Sleep quality, posttraumatic stress, depression, and human errors in train drivers: a population-based nationwide study in South Korea

European neuropsychopharmacology, 2014-10, Vol.24, p.S354-S354

2014

Volltextzugriff (PDF)

SAMe and sexual functioning

European psychiatry, 2012-08, Vol.27 (6), p.451-454

2012

Volltextzugriff (PDF)

P.2.b.004 Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: tianeptine versus escitalopram

European neuropsychopharmacology, 2013-10, Vol.23, p.S320-S321

2013

Volltextzugriff (PDF)

Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder

European psychiatry, 2012-10, Vol.27 (7), p.518-521

2012

Volltextzugriff (PDF)

Role of S-adenosyl-l-methionine in the treatment of depression: a review of the evidence

The American journal of clinical nutrition, 2002-11, Vol.76 (5), p.1158S-1161S

2002

Volltextzugriff (PDF)

Docosahexanoic acid and omega-3 fatty acids in depression

The Psychiatric clinics of North America, 2000-12, Vol.23 (4), p.785-794

2000

Volltextzugriff (PDF)

Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial

Journal of affective disorders, 2019-02, Vol.245, p.1007-1015

2019

Volltextzugriff (PDF)

The potential relationship between levels of perceived stress and subtypes of major depressive disorder (MDD)

Acta psychiatrica Scandinavica, 2004-12, Vol.110 (6), p.465-470

2004

Volltextzugriff (PDF)

Longer-term open-label study of adjunctive riluzole in treatment-resistant depression

Journal of affective disorders, 2019-11, Vol.258, p.102-108

2019

Volltextzugriff (PDF)

Cell-extracellular matrix interactions can regulate the switch between growth and differentiation in rat hepatocytes: reciprocal expression of C/EBP alpha and immediate-early growth response transcription factors

Molecular and Cellular Biology, 1994-09, Vol.14 (9), p.5858-5869

1994

Volltextzugriff (PDF)

Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial

European neuropsychopharmacology, 2018-10, Vol.28 (10), p.1126-1136

2018

Volltextzugriff (PDF)

The role of folate in depression and dementia

The journal of clinical psychiatry, 2007, Vol.68 Suppl 10, p.28

2007

Volltextzugriff (PDF)

The Massachusetts General Hospital Guide to Depression: New Treatment Insights and Options

1st ed. 2019., 2018

Volltextzugriff (PDF)

P.010 Dose increase of s-adenosyl-methionine and escitalopram in a randomized clinical trial for major depressive disorder

European neuropsychopharmacology, 2019-12, Vol.29, p.S26-S27

2019

Volltextzugriff (PDF)

1 – 25 von 130

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(102)

Publikationsform

Artikel
(108)
Buchkapitel
(21)
Bücher
(1)

Sprache

Englisch
(130)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(106)
Science & Technology
(106)
Psychiatry
(99)
Humans
(71)
Depression
(48)
Female
(44)
Male
(44)
Adult
(35)
Middle Aged
(35)
Social Sciences
(35)
Biological And Medical Sciences
(34)
Depressive Disorder, Major - Drug Therapy
(32)
Medical Sciences
(32)
Psychology
(31)
Treatment Outcome
(30)
Psychology, Clinical
(29)
Psychology. Psychoanalysis. Psychiatry
(28)
Psychopathology. Psychiatry
(23)
Neurosciences & Neurology
(21)
Pharmacology. Drug Treatments
(20)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study

A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients

Interleukin-6 receptor antagonists in immunopsychiatry: Can they lead to increased interleukin-6 in the central nervous system (CNS) and worsening psychiatric symptoms?

Dissociable cortico-striatal connectivity abnormalities in major depression in response to monetary gains and penalties

Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression

Reduced frontal-subcortical white matter connectivity in association with suicidal ideation in major depressive disorder

Complementary Medicine, Exercise, Meditation, Diet, and Lifestyle Modification for Anxiety Disorders: A Review of Current Evidence

St John's wort (Hypericum perforatum) versus sertraline and placebo in major depressive disorder: continuation data from a 26-week RCT

Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re-Analysis of Data from a Randomized Clinical Trial

Corrigendum to “Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants” [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1]

A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients

P.1.k.023 Sleep quality, posttraumatic stress, depression, and human errors in train drivers: a population-based nationwide study in South Korea

SAMe and sexual functioning

P.2.b.004 Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: tianeptine versus escitalopram

Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder

Role of S-adenosyl-l-methionine in the treatment of depression: a review of the evidence

Docosahexanoic acid and omega-3 fatty acids in depression

Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial

The potential relationship between levels of perceived stress and subtypes of major depressive disorder (MDD)

Longer-term open-label study of adjunctive riluzole in treatment-resistant depression

Cell-extracellular matrix interactions can regulate the switch between growth and differentiation in rat hepatocytes: reciprocal expression of C/EBP alpha and immediate-early growth response transcription factors

Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial

The role of folate in depression and dementia

The Massachusetts General Hospital Guide to Depression: New Treatment Insights and Options

P.010 Dose increase of s-adenosyl-methionine and escitalopram in a randomized clinical trial for major depressive disorder

Suchergebnisse filtern